Amikacin — разлика између измена

 

<!--Pharmacokinetic data-->

| protein_bound = 0-11%

| elimination_half-life = 2-3 sata

| excretion = [[Bubreg|Renalno]]

| ATC_prefix = D06

| ATC_suffix = AX12

| PubChem = 37768

| IUPHAR_ligand =

'''Amikacin''' je [[aminoglikozid]]ni [[antibiotik]] koji se koristi za tretiranje različitih tipova [[bakterija|bakterijskih]] [[infekcija]]. Amikacin deluje putem vezivanja za bakterijsku -{[[30S]]}- [[ribozom]]alnu podjedinicu, čime uzrokuje pogrešno očitavanje [[iRNK]] te time onemogućava bakterijsku sintezu [[protein]]a koji su vitalni za njen rast.

 

Amikacin se najčešće koristi za tretiranje ozbiljnih, u bolnici stečenih infekcija uzrokovanih [[Gramnegativna bakterija|gramnegativnim]] bakterijama otpornim na višestruke lekove kao što su -{''[[Pseudomonas aeruginosa]]'', ''[[Acinetobacter]]''}-, i -{''[[Enterobacter]]''}-. Takođe je efektivan protiv -{''[[Serratia marcescens]]''}- i -{''[[Providencia stuartii]]''}-. Amikacin se može koristiti za tretiranje netuberkularnih mikobakterijskih infekcija i tuberkuloze (ako je uzrokovana senzitivnim vrstama) kad drugi lekovi nisu uspešni.

 

Lipozomalni amikacin za inhaliranje je trenutno u završnom stadijumu kliničkih ispitivanja za tretman respiratornih bolesti, kao što je [[cistična fibroza]]<ref>-{[https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000441-20/GB "Randomized, open-label, active-controlled, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas aeruginosa"] is a European Phase III clinical trial, being conducted across multiple sites in the EU, starting at the Royal Brompton Hospital, Department of Respiratory Medicine, in London}-</ref>, -{''[[Pseudomonas aeruginosa]]''}-<ref>[http://www.clinicaltrials.gov/ct2/show/NCT01315678 -{Study to Evaluate Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections}-]</ref>, netuberkularnih mikobakterijskih infekcija<ref>-{[http://www.clinicaltrials.gov/ct2/show/NCT01315236 "A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikace™) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease"] is a Phase II clinical trial in collaboration with the US National Institute of Allergy and Infectious Diseases}-</ref> i [[Bronhiektazija|bronhiektazije]].<ref>-{[http://www.clinicaltrials.gov/ct2/show/NCT00775138 "A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa"] Phase II (completed).}-</ref><ref>-{[http://www.ukctg.nihr.ac.uk/trialdetails/NCT00775138 "A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis"] is a Phase II clinical trial (as [4]) completed in the UK.}-</ref>

 

 

== Literatura ==